Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Phase 3

Withdrawn

Conditions: Purpura
Idiopathic Thrombocytopenic Purpura

Interventions: Drug: All-Trans Retinoid Acid(ATRA)
Drug: Dexamethasone

First Posted Date: 2013-06-20

Last Posted Date: 2016-04-20

Lead Sponsor: Shandong University

Registration Number: NCT01882127

Locations: 🇨🇳
Qilu Hospital, Shandong University, Jinan, Shandong, China

Dexamethasone for Post Cesarean Delivery Analgesia

Phase 4

Completed

Conditions: Postoperative Pain

Interventions: Drug: Placebo
Drug: Dexamethasone

First Posted Date: 2013-06-04

Last Posted Date: 2017-09-19

Lead Sponsor: University of Iowa

Target Recruit Count: 52

Registration Number: NCT01868633

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Bortezomib
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Other: Quality-of-Life Assessment
Other: Laboratory Biomarker Analysis

First Posted Date: 2013-05-29

Last Posted Date: 2024-11-28

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 1087

Registration Number: NCT01863550

Locations: 🇺🇸
FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst, North Carolina, United States
🇺🇸
Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States
🇺🇸
Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States

and more 913 locations

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Phase 1

Active, not recruiting

Conditions: Amyloidosis
Plasma Cell Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2013-05-29

Last Posted Date: 2025-01-07

Lead Sponsor: Mayo Clinic

Target Recruit Count: 87

Registration Number: NCT01864018

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

Phase 2

Active, not recruiting

Conditions: Cholangiolar Carcinoma
Cholangiocellular Carcinoma
Peripheral Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma

Interventions: Drug: Floxuridine (FUDR)
Drug: dexamethasone
Drug: Gemcitabine
Drug: Oxaliplatin
Other: MRI
Other: Research blood draws

First Posted Date: 2013-05-24

Last Posted Date: 2024-07-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 55

Registration Number: NCT01862315

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States

and more 2 locations

Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2013-05-20

Last Posted Date: 2024-11-13

Lead Sponsor: European Myeloma Network B.V.

Target Recruit Count: 63

Registration Number: NCT01857115

Locations: 🇮🇹
Fondazione EMN Italy Onlus, Torino, Italy

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

Phase 2

Completed

Conditions: CINV

Interventions: Drug: Ondansetron
Drug: Dexamethasone
Drug: Placebo
Drug: Fosaprepitant
Drug: APD403 IV
Drug: APD403 oral

First Posted Date: 2013-05-20

Last Posted Date: 2020-11-25

Lead Sponsor: Acacia Pharma Ltd

Target Recruit Count: 342

Registration Number: NCT01857232

Locations: 🇩🇰
Odense University Hospital, Odense, Denmark

Ovulation Induction With Clomiphene Citrate and Dexamethasone

Phase 4

Conditions: Infertility

Interventions: Drug: Placebo
Drug: Dexamethasone

First Posted Date: 2013-05-17

Last Posted Date: 2014-02-28

Lead Sponsor: San Antonio Military Medical Center

Target Recruit Count: 140

Registration Number: NCT01856062

Locations: 🇺🇸
San Antonio Military Medical Center, Ft. Sam Houston, Texas, United States

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Placebo
Drug: Ixazomib
Drug: Dexamethasone
Drug: Lenalidomide

First Posted Date: 2013-05-09

Last Posted Date: 2023-07-21

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 705

Registration Number: NCT01850524

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Stage III Multiple Myeloma
Isolated Plasmacytoma of Bone
Primary Systemic Amyloidosis
Extramedullary Plasmacytoma
Light Chain Deposition Disease
Stage I Multiple Myeloma
Stage II Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: cisplatin
Drug: doxorubicin
Drug: cyclophosphamide
Drug: etoposide
Drug: bortezomib
Drug: thalidomide
Drug: melphalan
Procedure: autologous stem cell transplant

First Posted Date: 2013-05-09

Last Posted Date: 2022-05-11

Lead Sponsor: Margarida Magalhaes-Silverman

Target Recruit Count: 41

Registration Number: NCT01849783

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy